Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice
Author(s) -
Zhuofeng Lin,
Xuebo Pan,
Fan Wu,
Dewei Ye,
Yi Zhang,
Yu Wang,
Leigang Jin,
Qizhou Lian,
Yü Huang,
Hong Ding,
Chris R. Triggle,
Kai Wang,
Xiaokun Li,
Aimin Xu
Publication year - 2015
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.115.015308
Subject(s) - fgf21 , medicine , endocrinology , adiponectin , apolipoprotein b , neointima , adipose tissue , ldl receptor , fibroblast growth factor , biology , lipoprotein , cholesterol , receptor , insulin resistance , insulin , stent , restenosis
Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity. It acts as a key downstream target of both peroxisome proliferator-activated receptor α and γ, the agonists of which have been used for lipid lowering and insulin sensitization, respectively. However, the role of FGF21 in the cardiovascular system remains elusive.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom